Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment

Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person ’s gut could help fight cancer. Under the three-year collaboration deal announced Monday, Seres (Nasdaq: MCRB) will evaluate how the bacteria found in the human body, also known as the microbiome, can help predict which patients respond to cancer immuno-therapies. AstraZeneca (NYSE: AZN) may also test Seres’ early-stage drug candidate, SER-401, in combination…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news